"The final rule for 2025 poses several challenges to urology. Lobbying efforts to preserve telehealth access and the CF will continue, perhaps dragging into 2025," write Jonathan Rubenstein, MD, and ...

OAB exhibits distinct pathophysiological differences in men and women, complicating diagnosis due to symptom overlap with BPH in men. Engaging patients in the diagnostic process is crucial for ...

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and ...

The PRESERVE trial evaluates Irreversible Electroporation for prostate tissue ablation, seeking a specific indication for prostate cancer treatment. Irreversible Electroporation is already ...

"Honestly, there really isn't another measure of sexual quality of life for females that addresses the specific concerns of the female partners of patients with prostate cancer," says Stacy Loeb, MD, ...

Management of mCSPC involves ADT combined with systemic therapies like docetaxel, abiraterone, enzalutamide, or apalutamide. These combination therapies improve overall survival and progression-free ...

What are the next steps for this research? I think the main question is, how does PSA-directed therapy and metastasis-directed therapy affect recurrent metastasis-free survival and survival outcomes ...

AI scribe technology at Emory University aids in efficient clinical note-taking, potentially enhancing physician satisfaction and reducing after-hours electronic health record usage. AI algorithms are ...

FK-PC101 is a personalized immunotherapy using irradiated autologous tumor cells to prevent prostate cancer recurrence post-prostatectomy. The CELLVX-230 trial, enrolling 100 high-risk patients, is ...

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

APPs manage non-surgical men's health procedures, including erectile dysfunction and low testosterone treatments, enhancing practice efficiency. Tasks like TRIMIX injections, Xiaflex injections, and ...

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and ...